Cangene (FRA:YGE) Change In Inventory : €0.19 Mil (TTM As of Oct. 2013)

View and export this data going back to . Start your Free Trial

What is Cangene Change In Inventory?

Cangene's change in inventory for the quarter that ended in Oct. 2013 was €-1.40 Mil. It means Cangene's inventory increased by €1.40 Mil from Jul. 2013 to Oct. 2013 .

Cangene's change in inventory for the fiscal year that ended in Jul. 2013 was €3.97 Mil. It means Cangene's inventory declined by €3.97 Mil from Jul. 2012 to Jul. 2013 .

Cangene's Total Inventories for the quarter that ended in Oct. 2013 was €39.85 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cangene's Days Inventory for the quarter that ended in Oct. 2013 was 319.10.

Inventory Turnover measures how fast the company turns over its inventory within a year. Cangene's Inventory Turnover for the quarter that ended in Oct. 2013 was 0.29.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cangene's Inventory-to-Revenue for the quarter that ended in Oct. 2013 was 2.21.

Cangene Change In Inventory Historical Data

The historical data trend for Cangene's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Change In Inventory Chart

Cangene Annual Data

Trend

Jul04

Jul05

Jul06

Jul07

Jul08

Jul09

Jul10

Jul11

Jul12

Jul13

Change In Inventory

Get a 7-Day Free Trial

-13.42

-3.11

13.10

7.76

3.97

Cangene Quarterly Data
	Jan09	Apr09	Jul09	Oct09	Jan10	Apr10	Jul10	Oct10	Jan11	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13
Change In Inventory	Get a 7-Day Free Trial															2.41	0.10	1.19	0.29	-1.40

Cangene Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Oct. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.19 Mil.

Cangene (FRA:YGE) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cangene's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	39.9605	/	11.427	*	365 / 4
	=	319.10

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cangene's Inventory Turnover for the quarter that ended in Oct. 2013 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	11.427	/	39.9605
	=	0.29

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cangene's Inventory to Revenue for the quarter that ended in Oct. 2013 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	39.9605	/	18.043
	=	2.21

Cangene Change In Inventory Related Terms

Thank you for viewing the detailed overview of Cangene's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Cangene (FRA:YGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cangene.com

Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines